NYSE · traded in Congress
Pfizer, PFE
$29.66 +0.27 (+0.92%) Nov 9, 2026 4:32 AM ET
Market value$169.1B
P/E ratio-
Analyst target$30.00
52-week range-
Avg volume27,470,701
Dividend yield-
Chart
Analyst ratings
- 9 buy
- 18 hold
- 3 sell
Low target$25.00
Average target$30.07
High target$37.00
Quarterly financials
| Quarter ended | Revenue | Gross profit | Net income | Net margin |
|---|---|---|---|---|
| $15,752M | - | $4,994M | 31.7% | |
| $22,638M | - | $8,608M | 38.0% | |
| $27,742M | - | $9,906M | 35.7% | |
| $25,661M | - | $7,864M | 30.7% |
Congress trades in PFE
Members of Congress disclosed 2 transactions in PFE in the filings we have processed.
| Traded | Member | Type | Amount | Filed |
|---|---|---|---|---|
| 03/13/2026 | Gilbert Cisneros CA31 | Partial sale | $1,001 - $15,000 | 4/7/2026 filing |
| 02/10/2026 | Gilbert Cisneros CA31 | Purchase | $1,001 - $15,000 | 3/9/2026 filing |
Disclosed under the STOCK Act. Amounts are the ranges the law requires, filings can lag a trade by up to 45 days, and a disclosure is not evidence of wrongdoing. All congressional trades ›
Our coverage
- Pfizer raises 2026 guidance as Eliquis jumps 25%, but revenue is flat and Covid still drags Stocks · November 3, 2026
- Before the bell: Oil jumps 2.7% and Dow futures drop 0.7% as Apple slides and America votes Markets · November 3, 2026
Other companies
Price and key figures from Nasdaq's public quote data, refreshed through the day; the chart is live from TradingView; options activity, ratings, financials, earnings and filings refreshed through the day. Congressional trades parsed from official House filings. Market information, not investment advice.
